[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
We studied the efficacy of mesna as a protectant for urotoxicity in pediatric patients receiving chemotherapy including oxazaphosphorines. Nineteen patients with malignant diseases (5 neuroblastoma, 3 acute lymphocytic leukemia, 4 acute non-lymphocytic leukemia, 2 non-Hodgkin lymphoma, 3 osteosarcoma and 2 rhabdomyosarcoma) were treated with a total of 106 courses of therapy between June of 1986 and May of 1989. Of these, no gross hematuria were seen. Microhematuria transiently occurred only in 2 courses (5%) of 1 patient (2%). These data indicated that mesna was highly effective for urotoxicity of oxazaphosphorines without any side effects, especially in pediatric patients.
Iwasaku-Fujimoto
M
M
Dept. of Pediatrics, Children's Research Hospital, Kyoto Prefectural University of Medicine.
Fujiwara
F
F
Todo
S
S
Morioka
Y
Y
Imashuku
S
S
D001859:Bone Neoplasms / Q000188:drug therapy; D002648:Child; D003520:Cyclophosphamide / Q000009:adverse effects*; D003556:Cystitis / Q000517:prevention & control*; D005260:Female; D006417:Hematuria / Q000517:prevention & control*; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects*; D007938:Leukemia / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000627:therapeutic use*; D009447:Neuroblastoma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy
D008623:Mercaptoethanol; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide